-
Luoxin Pharmaceutical's Edaravone Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-05-29
On January 9, Luoxin Pharmaceutical announced that its subsidiary Shandong Luoxin had recently received the "Approval Notice for Supplementary Drug Application" for Edaravone Injection approved and issued by the State Food and Drug Administration .
-
80% of China's clinical data are not true is the "evidence" or "examination" of Innovent's rejection
Time of Update: 2022-05-29
Once again aroused discussion in the industry, this is definitely the real situation of China's new drug clinical research?It is not difficult for careful readers to find that the report data cited by the FDA is the 2016 report of the China Food and Drug Administration .
-
International recognition of clinical research on Chinese medicine for treating hypertension
Time of Update: 2022-05-29
Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial" clinical research paper, Chinese medicine treatment of essential hypertension adds high-quality clinical evidence, and the results have been recognized by international authoritative journals .
A randomized, double-blind, double-dummy, multicenter clinical study in patients with essential hypertension (grade 1) .
-
Eli Lilly's third COVID-19 neutralizing antibody receives FDA emergency use authorization for Omicron
Time of Update: 2022-05-29
Recently, Eli Lilly announced that its new crown neutralizing antibody bebtelovimab has been granted Emergency Use Authorization (EUA) by the FDA for the treatment of patients with mild to moderate new coronary pneumonia .
-
Shanghai's newly added medical insurance negotiation drug dupilimumab injection is listed on the Internet
Time of Update: 2022-05-29
The specifications and packaging are - 1.
In addition, the "Shanghai Pharmaceutical Procurement Service and Supervision Information System" will push the drug information to the hospital, which will take effect on February 17, 2022 .
-
Puli Pharmaceutical's Esomeprazole Sodium for Injection was officially approved by the FDA
Time of Update: 2022-05-29
As an alternative therapy for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis (EE) in adults and children aged 1 month to 17 years when oral therapy is not appropriate .
-
AbbVie's JAK inhibitor "Upatinib Sustained-Release Tablets" is expected to be approved in China in the near future
Time of Update: 2022-05-29
It is hoped that AbbVie Upatinib Sustained-Release Tablets will be approved in China as soon as possible, which will provide new treatment options for Chinese patients with atopic dermatitis!References:[1] Drug registration progress query on NMPA official website.
-
Yifan Pharmaceutical's Cefuroxime Sodium for Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-05-29
Cefuroxime sodium for injection is a second-generation cephalosporin antibiotic, mainly used for infections caused by sensitive bacteria, including respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, gonorrhea, Bone and joint infections, puerperium and gynecological infections .
com, the sales of cefuroxime sodium for injection in China in 2019 and 2020 were 5.
-
Qilu Ruige CDK2/4/6 inhibitor RGT-419B was reported for the first time in China
Time of Update: 2022-05-29
The clinical development program for RGT-419B will address this resistance to CDK4/6 and other hormone receptor modulating therapies, providing new opportunities to improve survival and quality of life for patients with advanced breast cancer .
-
Complement drug development is getting better
Time of Update: 2022-05-28
In terms of indications, although the indications under development are still mainly for rare diseases with approved first-in-class drugs, applications in some common diseases are also being actively explored, including the complications of COVID-19 caused by the new crown epidemic.
Global clinical stage complement pathway targeted drugsSource: CPM New Drug Development Monitoring Database
-
Treat Heart Failure!
Time of Update: 2022-05-28
On February 23, the China Drug Clinical Trial Registration and Information Publicity Platform showed that Xinlitai Pharmaceutical has launched a Phase 3 clinical study of S086 tablets in the treatment of patients with heart failure with reduced ejection fraction (HFrEF), and plans to enter the drug in China.
-
Will the implementation of high-priced HPV vaccines be completely reduced to "chicken ribs" for free vaccination?
Time of Update: 2022-05-28
For example, on November 16, Guangdong plans to launch a free HPV vaccination program for school-age girls in the province, and the stock price of Wantai Bio, a domestic HPV vaccine company, rose to the daily limit .
-
Bayer withdraws PI3K inhibitor application for one indication
Time of Update: 2022-05-28
Bayer submitted the first domestic application for the product in March 2021 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two systemic therapies in the past.
-
What exactly should "hot" modified drugs do?
Time of Update: 2022-05-28
Data source: Xianda Pharmaceutical DataAs shown in the table above, the most approved improved drugs in China are the drugs with new indications in category 2.
If it is to change the dosage form between oral drugs, it is mainly to do bioequivalence studies at present .
-
Sprint for A shares!
Time of Update: 2022-05-28
According to the prospectus, from January to June 2021, Fujilai's main business income was 257 million yuan, and the net profit attributable to the parent was 62.
-
Watson Bio's bivalent HPV vaccine is about to be approved
Time of Update: 2022-05-28
In terms of development time, this bivalent HPV vaccine was approved for clinical trials as early as June 1, 2011 .
-
AbbVie Upatinib Approved in my country to Inventory 8 Iteratively Marketed JAK Inhibitors Worldwide
Time of Update: 2022-05-28
0202Approved JAK inhibitors in my country and their research statusApproved JAK inhibitors in my country and their research statusWith the approval of AbbVie Upatinib, 4 JAK inhibitors have been approved in China, and the remaining 3 are: Novartis' ruxolitinib, Eli Lilly's baricitinib, and Pfizer's tofacitinib Cloth, the indications mainly cover rheumatoid arthritis, myelofibrosis, atopic dermatitis .
-
155 biopharmaceutical companies raise drug prices!
Time of Update: 2022-05-28
Top 10 drugs with rising pricesSome of the more well-known and expensive brands, such as the anti-PD-1 drugs Opdivo and Jemperli, have previously been known for their expensive prices, and the prices of these two therapies are They rose again in the new year, with gains of 2% and 2.
-
Puli Pharmaceutical's Pantoprazole Sodium for Injection received MHRA marketing authorization
Time of Update: 2022-05-28
On February 23, Puli Pharmaceutical announced that the company has recently received the marketing authorization of pantoprazole sodium for injection issued by the British MHRA, and the indications are gastric and duodenal ulcers, reflux esophagitis; Zorin.
-
New migraine favorite CGRP receptor antagonist Aimovig's sales are overtaken by Emgality
Time of Update: 2022-05-28
With the announcement of major companies' 2021 financial reports, the sales rankings of the above-mentioned CGRP receptor antagonists have also been released, as detailed in the table below .
